Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2026/06/30

The report presents the company’s governance structure, the skills composition of its directors and executive officers, and its timely disclosure framework in charts and tables. No specific changes from the previous report are stated.

Worth reading
85Important
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors9 directors in total, including 4 outside directors
Committee5
Nomination and Compensation Committee (percentage of outside committee members: 非開示)Audit and Supervisory CommitteeRisk Management CommitteeCompliance Committeeand Sustainability Committee (percentage of outside committee members for each committee: 非開示)
Changes this time

Changes from the previous report: Not disclosed

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors9 directors in total, including 4 outside directors
CommitteeNomination and Compensation Committee (percentage of outside committee members: Not disclosed), Audit and Supervisory Committee, Risk Management Committee, Compliance Committee, and Sustainability Committee (percentage of outside committee members for each committee: Not disclosed)
Changes this timeChanges from the previous report: Not disclosed
Items this document does not state (4)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/06/30 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori